Drug Profile
Research programme: hepatitis C therapies - Merck
Alternative Names: HCV NS5A inhibitors - Idenix; IDX 19368; IDX 316; IDX-136; IDX-20963; IDX077; IDX102; IDX791; IDXSCA; IDXSCB; NV 08; NV 08B; Uridine nucleoside - Idenix; Uridine nucleotide analog - Idenix; Uridine nucleotide prodrug - IdenixLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Idenix Pharmaceuticals; University of Cagliari
- Developer Merck & Co
- Class Macrocyclic compounds; Nucleosides
- Mechanism of Action Hepatitis C protease inhibitors; Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus replication inhibitors; Polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis C